Introduction
Apoptosis is a genetically regulated form of cell death that plays an important role in eliminating infected, damaged, and other unwanted cells from the body (Kerr et al., 1972) . With the realization that defects in apoptosis can contribute to diseases like cancer, interest in the control of apoptosis has grown exponentially among cancer researchers. Apoptosis can be triggered by various extracellular and intracellular stimuli that result in coordinated activation of a family of cysteine proteases called caspases.
About 14 caspases have been described so far in mammalian systems (Evan and Littlewood, 1998; Johnstone et al., 2002; Eckhart et al., 2000; Ahmad et al., 1998) . On the basis of their role in apoptosis, caspases can be categorized into two major subgroups. The upstream or initiator caspases (e.g., caspase-8, -9 and -10) are activated by apoptotic signals, resulting in the activation of the downstream or executioner caspases (Nicholson, 1999) . Following their activation, the executioner caspases, which include caspase-3, -6 and -7, catalyze the specific cleavage of many key cellular proteins, such as poly(ADP-ribose) polymerase, inhibitor of caspase-activated DNase, gelsolin, 4-GDI, a-and b-fodrin, and epidermal growth factor receptor (Thorneberry and Lazebnik, 1998; Cryns and Yuan, 1998) . The cleavage of these proteins results in membrane blebbing, chromatin condensation, and DNA fragmentation, the hallmark changes associated with apoptosis. A mitochondrial flavoprotein, apoptosis-inducing factor (AIF), can also induce morphological apoptosis in a caspaseindependent manner in response to certain apoptotic stimuli (Cande et al., 2002) . Nevertheless, caspase-3 (also known as CPP32, Yama, and apopain) is considered to be the central protein in the execution of apoptosis (Enari et al., 1996) and to play a pivotal role in the development of the central nervous system. For example, caspase-3 knockout mice exhibited decreased apoptosis in the brain and died prematurely (Kuida et al., 1996) .
Genetic or epigenetic alterations that disrupt the ability of cells to undergo apoptosis can lead to the development of cancer. For example, p53 is frequently mutated in aggressive and in chemoresistant tumors. The expression of Apaf-1, a cell-death effector that acts with cytochrome-c and caspase-9 to mediate p53-dependent apoptosis is lost in metastatic melanomas (Soengas et al., 2001) . Similarly, the gene for the effector caspase-8 is frequently inactivated in childhood neuroblastomas (Teitz et al., 2000) . Moreover, resistance to apoptotic stimuli has been reported frequently in MCF-7 human breast carcinoma cells that lack expression of caspase-3 as a result of a 47 bp deletion in exon 3 of the CASP3 gene (Janicke et al., 1998; Yang et al., 2001) .
Considering the central role caspase-3 plays in executing apoptosis and the observation that several established breast cancer cell lines exhibit altered caspases-3 expression, we examined the expression of caspase-3 in freshly isolated normal and malignant breast tissue samples. Our results revealed some interesting findings; specifically, approximately 75% of the breast tumor samples lacked the caspase-3 transcript and expression of caspase-3 protein, while the remaining samples showed substantial decreases in caspase-3 expression. More interestingly, a similar loss in caspase-3 expression was evident in morphologically normal peritumoral tissue samples obtained from breast cancer patients. These results suggest that loss of caspase 3 expression may represent an important mechanism of cell survival and chemoresistance by breast cancer cells.
Results

Caspase-3 expression in breast cancer cell lines
As our first step in determining the levels of caspase-3 in breast cancer cells, we performed Western blot analysis on a panel of human mammary cancer cell lines (Figure 1) . Most of the cell lines that we studied contained abundant levels of caspase-3 protein. The three normal human breast epithelial cell lines (MCF10A and the two finite-life-span epithelial cell lines obtained from Clonetics, San Diego, CA, USA) showed considerable levels of caspase-3 protein expression. However, as previously reported (Janicke et al., 1998) , MCF-7 cells completely lacked caspase-3 protein expression (Figure 1 ). Interestingly, two other breast cancer cell lines, BT-20T and ZR-75T, also showed a complete lack of caspase-3 protein expression ( Figure  1 ). Using caspase-3-specific primers, RT -PCR analysis of these two cell lines demonstrated a truncated (approximately 750 bp) transcript that upon sequencing revealed a 125 bp deletion from position 54 in Pro18 to position 178 in Gly60 (unpublished observations). As previously observed (Janicke et al., 1998) , the shift in the open reading frame resulting from this deletion may account for the loss of procaspase-3 protein in BT-20T and ZR-75T cells. Western blot analysis also revealed that the levels of caspases-3 protein expression in some other breast cancer cell lines (Hs854T, HCC1428, BT549, and BT483) were on average five to seven times lower than those in the NME cells (Figure 1 ).
Expression of caspase-3 in human breast cancer
In view of the various caspase-3 protein expression levels and transcript sizes in different breast cancer cell lines, we next determined whether similar variations could occur in human breast cancer cells. Breast tissue specimens were collected from a total of 46 patients, including 31 with adenocarcinoma (four of whom had received preoperative chemotherapy), ten with a history of breast cancer, three with benign breast disease, and two undergoing breast reduction surgery. Clinical and pathologic data, including TNM stage, hormone receptor (estrogen receptor (ER) and progesterone receptor (PR)) status, and Her-2 expression levels from the 31 patients with adenocarcinoma are shown in Table 1 . Total RNA was extracted from benign and malignant tissue samples, and RT -PCR using caspase-3-specific primers was performed. The results shown in Figure 2a , and Table 1 revealed that about 75% of the breast tumor samples lacked caspase-3 transcript; the remaining 25% had detectable expression levels of caspase-3 mRNA, albeit the levels were significantly lower than those observed in the NME cells.
Morphologically normal breast parenchyma samples obtained from the vicinity of the tumor tissue showed similar lack of or reduction in caspase-3 expression (Figure 2b) . Out of the 12 such samples studied (from patients #1 -12; Table 1 ), only one demonstrated detectable caspase-3 expression by RT -PCR analysis. On the other hand, a substantial number (seven out of 10) of normal tissue samples obtained from patients who had a history of breast cancer and had undergone Figure 1 Levels of caspase-3 protein expression in various breast cancer cell lines were detected using Western blot analysis. Sixty micrograms of sample protein was applied in each lane and fractionated on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes, and probed with an anti-caspase-3 antibody as described in Materials and methods. The membranes were stripped and reprobed with bactin antibody to ensure even loading Caspase-3 in breast cancer E Devarajan et al Morphologically normal breast parenchyma samples were obtained from patients who had undergone tumor resection surgery in the past. Table 1 ) showed detectable levels of caspases-3 expression. As a control, we used the normal breast tissue samples obtained from the patients undergoing breast reduction surgery (patients #45 and 46; Table 1) or from patients with benign breast disease (patients #42 -44 and second breast from patient #4; Table 1 ). All the five normal breast tissue samples showed strong levels of caspase-3 transcript expression (Table 1 ; Figure 2c ).
The loss of caspase-3 expression in breast cancer cells was further confirmed by Northern blot analysis. The results shown in Figure 3 , clearly demonstrated that caspase-3 mRNA expression levels in breast tumors were at least 10 -50 times lower than those in normal breast tissue or breast cancer cell lines. Specifically, MCF-7 cells showed truncated caspase-3 mRNA due to a 125 bp deletion in the transcript (Janicke et al., 1998) . Nevertheless, MCF-7/DOX cells that were derived via continuous culture of MCF-7 cells in the presence of doxorubicin, exhibited a fulllength caspase-3 transcript ( Figure 3a ) as previously demonstrated (Pirnia et al., 2000; Devarajan et al., 2002) . We also tested the commercially available total RNA samples that had been isolated from the human breast, cervical, uterine, and ovarian tumors (Clontech Laboratories). To our surprise, the RNA samples isolated from not only the breast tumor sample but also cervical tumor samples, lacked detectable caspase 3 mRNA levels ( Figure 3a ). The RNA sample from ovarian tumors contained approximately four times lower caspase 3 mRNA than the uterine tumor sample, which was the only tumor sample that we tested, exhibited substantial levels of the caspase-3 transcript. However, a strong signal for caspase-3 mRNA was detected in various normal tissue samples, including the mammary gland, when the human Multiple Tissue Northern blot was probed under identical conditions ( Figure 3b ). The status of caspase-3 transcript expression in breast tissue samples was further determined by in situ RT -PCR analysis, using paraffin-embedded tissue sections. Figure 3b shows the caspase-3 transcript expression in representative breast tissue samples from a normal and a cancer patient. The in situ RT -PCR analysis further confirmed the deficient status of caspase-3 transcript expression in breast tumor. The caspase-3 expression in normal breast sample was restricted mainly to the ductal epithelial and myoepithelial cells (Figure 3b) .
Next, we determined the caspase-3 protein levels in breast cancer samples by using immunoblot analysis. No immunoreactive band corresponding to the authentic procaspase-3 protein (32 kDa) was evident in any of the six breast tissue samples ( Figure 4A ) that were negative for caspase-3 expression according to RT -PCR analysis (Table 1) . Under similar conditions, however, the cell lysates from a prostate cancer LNCaP cell line that we used as a positive control, showed a strong immunoreactive band corresponding with procaspase-3 protein (Figure 4a) . Similarly, the extracts from breast tissue samples that exhibited caspase-3 Figure 2 RT -PCR analysis of messenger RNA (mRNA) using primers specific for caspase-3 in breast tumor (a), adjacent normal (b), and normal mammary (c) tissue samples. Drug-sensitive (MCF-7) and drug-resistant (MCF-7/DOX) MCF-7 cells were used as positive controls for amplification of the truncated and full-length caspase-3, respectively. Amplification of b-actin was serially analysed for all of the samples to normalize for mRNA integrity and equivalent loading. M represents the 0.1 kb DNA ladder and Pt denotes patient (Table 1) , also showed a 32 kDa immunoreactive band, corresponding to procaspase-3 protein (Figure 4b) . A similar 32 kDa band was detected in extracts from the NME cells but MCF-7 cells completely lacked its expression, probably due to the 125 bp deletion in the transcript.
Effect of caspase-3 reconstitution on apoptosis
In order to determine the significance caspase-3 downregulation in breast cancer, we compared the ability of caspase-3-deficient and caspase-3 reconstituted MCF-7 cells to undergo apoptosis in response to calcium ionophore A23187 and staurosporine treatment. To reconstitute caspase-3, MCF-7 cells were transfected with pBabe/puro retroviral vector plasmid encoding a full-length procaspase 3 cDNA (pBS-CPP32) or empty vector (pBS) (Figure 5a ). Flow cytometry analysis of ionophore A23187 (2 mM, 48 h) and staurosporine (50 nM, 48 h)-treated MCF-7 cells revealed significant apoptosis (accumulation in sub-G1 phase) in pBS-CPP32-transfected MCF-7 cells; MCF-7/pBS control cells under similar conditions showed no appreciable apoptosis (Figure 5b,c) . Similarly, the multidrug resistant MCF-7/DOX cells which contain constitutive expression of caspase-3 protein (Devarajan et al., 2002) , showed comparable apoptosis to pBS-CPP32 transfected MCF-7 cells in response to A23187 (Figure 5b ) or staurosporine treatment (Figure 5c ). Moreover, the treatment of MCF-7/DOX and MCF-7/ pBS-CPP32 cells with ionophore A23187 yielded active fragments of caspase-3, as determined by a decrease or disappearance of the procaspase-3 32 kDa band by Western blot (data not shown). As previously reported (Yang et al., 2001) , the MCF7/pBS-CPP32 cells exhibited at least 2 -3-fold higher sensitivity towards doxorubicin-induced killing effect when compared with the control MCF-7/pBS cells (data not shown). These results suggested that lack of caspase-3 could render breast cancer cells resistant to doxorubicin as well as to other apoptotic stimuli. Finally, to determine whether the loss of caspase-3 expression represented a selective lesion in breast cancer patients, we tested some caspase-3-negative tumor samples for the expression of other caspases. The results shown in Figure 6 demonstrated that, despite a complete lack of procaspase-3 expression, the breast tumors had high levels of procaspase-9 and -8 expression. These results suggested that the loss of caspase-3 expression represents a selective event in breast cancer cells.
Discussion
It is now becoming apparent that many drugs can kill tumor cells by activating common apoptotic pathways (Hickman, 1996; Clynes et al., 1998) . Thus, somatic, genetic or epigenetic alterations that disable apoptosis can produce multidrug resistance. In this study, we demonstrate one such defect in breast cancer cells that can attenuate drug-induced apoptosis. A significant majority of the human breast tumors tested lacked caspase-3 expression. Caspase-3 is a member of the cysteine protease family, which plays a central role in the execution of apoptosis. We studied caspase-3 expression in breast cancer cells partly because of its important role in apoptosis but more so because in several of the breast cancer cell lines that we studied it was either altered or lost (Figure 1) . Additionally, caspase-3 activation has been detected in response to a variety of apoptotic stimuli, including chemotherapeutic agents, irradiation, and cytokines (Salvesen and Dixit, 1997). Conversely, selective inhibition of caspase-3 has been associated with inhibition of cell death (Hasegawa et al., 1996; Silke et al., 2001 ). These observations imply that loss of caspase-3 expression may render breast cancer cells resistant to chemotherapy and radiation therapy. Indeed, MCF-7 cells, which lack caspase-3 expression as a result of a functional deletion mutation in the CASP3 gene, are relatively insensitive to cisplatin, doxorubicin and etoposide. However, reconstitution with caspase-3 rendered MCF-7 cells sensitive to these and various other apoptotic stimuli (Figure 6 ) (Yang et al., 2001) . Conversely, despite the lack of caspase-3 expression, MCF-7 cells undergo morphological apoptosis in response to a variety of agents (Eck-Enriquez et al., 2000) . It is likely that these agents can induce apoptosis Figure 4 Western blot analysis of breast tissue samples for caspase-3 protein expression. Breast carcinoma (T) or adjacent normal (N) tissue samples obtained from breast cancer patients were homogenized in buffer, and 60 mg of homogenate protein was separated on an sodium dodecyl sulphate polyacrylamide gel electrophoresis. The membranes were probed with an anti-caspase-3 antibody. (a) Breast tissue samples that showed no detectable caspases-3 transcript levels by RT -PCR analysis (Table 1) . (b) Breast tissue samples that showed detectable caspase-3 transcript levels. The finite-life-span NME and LNCap cells showed a strong 32 kDa immunoreactive band corresponding with caspase-3 protein. Wild-type MCF-7 cells completely lacked caspase-3 protein expression. The membranes were stripped and reprobed with anti-b actin antibody to confirm equal protein loading and even transfer. Pt denotes patient, (N) denotes adjacent normal tissue sample, (T) denotes tumor sample, and NME denotes normal mammary epithelial cells Caspase-3 in breast cancer E Devarajan et al either in a caspase-independent manner (for example via AIF; Cande et al., 2002) or may involve alternative downstream caspases, such as caspase-6 and -7 (Liang et al., 2001) . Nevertheless, drug-resistant breast cancer cells could be rendered sensitive to epirubin, taxol, and ectoposide simply by overexpressing the caspase-3 protein (Friedrich et al., 2001) .
Another interesting aspect of this study was the observation that caspase-3 expression is also lost in normal looking breast parenchyma from breast cancer patients. Out of the twelve patients from whom such samples were obtained in this study, only one (patient #10) showed detectable levels of caspase-3 expression by RT -PCR analysis (Table 1 ). In contrast, seven (patients #34 -40) out of ten normal breast parenchyma tissue samples studied from patients who had undergone surgical tumor resection, showed normal levels of caspases-3 expression. The two normal breast tissue samples obtained during breast reduction surgery (patients #45 and 46) showed normal caspase-3 expression levels by RT -PCR (Figure 2c ) and immunoblotting ( Figure 4b) . Interestingly, the normal contralateral breast tissue sample from one patient (patient #4) exhibited a detectable level of caspase-3 transcript (Table 1) ; whereas both the tumor sample and the adjacent normal parenchyma sample from the same patient but obtained from the tumor-affected side showed a complete loss of caspases-3 expression. Moreover, substantial caspase-3 expression levels were observed in breast tissue samples obtained from three individuals (patients #42 -44) who did not have neoplastic breast disease. These results suggest that a lack of caspase-3 can attenuate apoptosis in response to certain stimuli, including chemotherapeutic drugs. Disruption of the intrinsic apoptotic pathways is frequently observed in cancer cells. For example, the tumor suppressor gene p53 is inactivated in more than 50% of human cancers, resulting in the removal of a key component of the DNA damage sensor that can induce the apoptotic effector cascade (Harris, 1996) . Conversely, the proteins that are known to serve as antiapoptotic survival signals, such as bcl-2, bcl-x, ras, and c-abl, are often overexpressed in tumor cells and cell lines (Martin and Green, 1995) . The correction of these alterations is associated with an increased propensity for the tumor cells to undergo apoptosis and re-establishes chemosensitivity (Johnstone et al., 2002; Wallace-Brodeur and Lowe, 1999) .
Importantly, the ability of cells to evade apoptosis is one of the essential hallmarks of cancer cells, the skill that can help them breach the anticancer defense mechanisms (Hanahan and Weinberg, 2000) . Thus, loss of expression of caspase-3 and/or other caspases may serve as a pivotal step in the survival of mutated somatic cells. Unlike that of caspase-3, the expression of caspase-8 and -9 was normal in breast tumor samples in the present study ( Figure 6 ). However, complete inactivation of the gene for caspase-8 was recently reported in neuroblastomas, a childhood tumor of the peripheral nervous system (Teitz et al., 2000) . Additionally, caspase-8-null neuroblastoma cells were resistant to doxorubicin-and death receptorinduced apoptosis. Furthermore, more than 80% of prostate tumors exhibit a complete lack of caspase-1 protein expression and reduced levels of caspase-3 expression (Winter et al., 2001) . Similarly, Apaf-1, a cell-death effector protein that acts in association with cytochrome-c and caspase-9, its expression is lost in the majority of metastatic melanomas (Soengas et al., 2001 ). These observations suggest that attenuation of apoptosis due to the inactivation or silencing of caspases may represent an important mechanism of cell survival and chemoresistance.
Our present findings are in contrast with those of an earlier report by Nakopoulou et al. (2001) . These authors employed an immunohistochemical assay to study caspase-3 protein expression in breast tumor samples and concluded that 75% of the breast tumors had higher levels of expression of this protein than the non-neoplastic breast tissue. Contrary to these findings, our results suggested that downregulation and deficiency of caspase-3 expression occurs in breast cancer cells and may represent a potential mechanism of cell survival. The observation of high caspase-3 expression by Nakopoulou et al. (2001) using immunohistochemical assay can be explained by possible cross reactivity of anti-caspase-3 antibody with some non caspase-3 protein in the breast tissue sections.
Finally, based on our preliminary results using the total RNA isolated from the breast, ovarian, cervical, and uterine carcinomas, it is likely that a similar loss or downregulation of caspase-3 expression may occur in other gynecologic tumors (Figure 3a) . At this point, we do not know the mechanisms that may underlie the loss of caspase-3 expression. CpG island hypermethylation, which is known to result in the silencing of several key genes in breast cancer (Huang et al., 1999) , might play a role. Indeed, silencing of the caspase-8 and caspase-1 genes was recently shown to result from hypermethylation in childhood neuroblastoma and renal cancer cells, respectively (Teitz et al., 2000; Ueki et al., 2001) . It is equally possible that some functional deletions in the CASP3 gene may result in the loss of its expression. For instance, a 124 bp deletion in the caspase-3 transcript in MCF-7 cells (Janicke et al., 1998) as well as in ZR-75T and BT-20T breast cancer cell lines (unpublished observations) results in a complete loss of caspase-3 protein expression ( Figure  1) . Moreover, we recently observed that some breast cancer patients harbor a 121 bp deletion (bp 483?604 ) in the active-site region of the caspase-3 transcript (unpublished observations). A similar deletion in the C-terminal end of the caspase-3 (casp3DC) transcript was observed by Huang et al. (2001) in a human colon carcinoma cell line; this deletion results from alternative mRNA splicing, and its product acts as a dominant, negative regulator, rendering the cells resistant to apoptosis.
In conclusion, our results suggest that the tumor cells as well as the normal parenchyma surrounding the tumor lack caspase 3 expression in the majority of breast cancer patients. As one would expect, loss of expression or function of this key caspase, can render breast cancer cells resistant to apoptosis in response to certain apoptotic stimuli including chemotherapeutic drugs and thus may affect the outcome and prognosis of the disease. These findings may have important clinical implications in terms of using caspase-3 not only as a marker of disease but also as a therapeutic target for breast cancer. Figure 6 Western blot analysis showing caspase-8 and -9 protein expression in caspase-3-negative breast tumor samples. Sixty micrograms of homogenate protein was separated on sodium dodecyl sulphate polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. Each membrane was probed with specific antibodies against caspase-9 (a) or caspase-8 (b). One of the membranes (a) was stripped and reprobed with anti-b actin antibody to confirm equal protein loading and even transfer (c).
Pt denotes patient
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Materials and methods
Cell lines and tissue samples
The human breast cancer cell lines T47D, MDA-MB-361, MDA-MB-468, and the mammary epithelial cell line, MCF10A were obtained from and maintained according to the instructions provided by the American Type Culture Collection (Rockville, MD, USA). In addition, the MDA-MB-134, Hs854T, HCC1954, HCC1428, DU4475, BT-549, and BT-483 breast cancer cell lines were provided by Dr J Dai (Yuan et al., 2001) , and BT-20T and ZR-75T cancer cell lines were provided by Dr K Keyomarsi (Chen et al., 2000) . Two normal mammary epithelial (NME) cell lines having a finite life span were purchased from Clonetics (San Diego, CA, USA). The drug-resistant MCF-7/DOX cell line was established via continuous culture of MCF-7 cells in the presence of doxorubicin as described previously (Devarajan et al., 2002) . The caspase-3 deficient MCF-7 cells were infected with either pBabe/puromycin retroviral vector alone (pBS) or vector containing full-length caspase-3 cDNA insert (pBS-CPP32), as described previously (Yang et al., 2001) .
Primary breast tumor and normal breast parenchyma samples (4 -6 mm 3 thick) were obtained from patients who had undergone breast surgery at The University of Texas MD Anderson Cancer Center. A total of 46 patients, including 31 having breast adenocarcinoma (four of whom had received preoperative chemotherapy), 10 with a history of breast cancer, three having benign breast disease, and two undergoing breast reduction surgery were enrolled in this pilot study. The median age of the patients was 55 years. The samples were obtained with the patients' consent following approval by the Institutional Committee for the Welfare of Human Subjects. Microscopic examination of representative sections of each sample after staining with hematoxylin and eosin stain confirmed the presence of carcinoma cells in greater than 80% of the sample area. The samples were either directly collected in RNAzol for immediate isolation of total RNA or snap frozen and stored at 7808C for later use.
Flow cytometric analysis of apoptotic cells
To determine the apoptosis, 1 -2610 6 cells were seeded into T-75 tissue culture flasks the day before treatment with 2 mM ionophore A23187 or 50 nM staurosporine (SSP) (both from Sigma). After 48 h treatment, free-floating cells were removed from the flasks and pooled with adherent cells obtained by trypsinization from the respective flasks. Pooled cells were permeabilized and incubated with 8 mg/ml acridine orange (Polysciences, Warrington, PA, USA). Cell fluorescence was measured using the logarithmic scale of the FACScan flow cytometer with a 488 nm excitation of a 15 mW argon laser and filter settings for green (530 nm; DNA) and red (585 nm; RNA) fluorescence. Ten thousand events were stored and run for analysis following the elimination of cell debris and doublets. The percentage of cells in the 'sub G1' region defined the proportion of apoptotic cells in the tested populations.
Reverse transcriptase-polymerase chain reaction (RT -PCR) analysis
RT -PCR analysis of caspase-3 transcript was carried out as described previously (Devarajan et al., 2002) . Briefly, total RNA was isolated from tissue samples or cells using the TRIzol method (Guo and Kyprianou, 1999) . RT -PCR was performed using 5 mg of total RNA and the Superscript II reverse transcript kit (Life Technologies, Grand Island, NY, USA) in an amplification cycler (Perkin-Elmer, Wellesley, MA, USA). The sequences of the caspase-3-specific primers used were as follows: sense, 5'-TTAATAAAGGTATC-CATGGAGAACACT-3'; and antisense, 5'-TTAGTGATA-AAAA TAGAGTTCTTTTGTGAG-3'. RT -PCR was performed at 948C for 2 min, 33 cycles at 948C for 1 min, at 558C for 1 min, and at 728C for 5 min. The integrity of the RNA used for RT -PCR was confirmed using b-actin synthesis as a positive control reaction (Haidar et al., 2000) . The amplified RT -PCR products were separated on a 1% agarose gel, stained with ethidium bromide for visualization, and photographed under ultraviolet illumination. For complementary DNA (cDNA) sequencing, the PCR products were subcloned into pCR2.1 plasmid (Invitrogen, Carlsbad, CA, USA) and sequenced in both directions using an automated DNA sequencer (310 Genetic Analyzer; Applied Biosystems, Foster City, CA, USA).
Northern blot analysis
Total RNA was isolated from primary breast tumor samples as described above. Also, to study caspases-3 expression in other gynecological tumors, total RNA isolated from human breast, cervical, ovarian, and uterine tumor tissues was purchased from Clontech Laboratories (Palo Alto, CA, USA). Ten micrograms of total RNA was mixed with the sample buffer (2.2 M formaldehyde, 50% formamide, 50 mM MOPS (pH 7.0) and 1 mM EDTA), denatured via heating at 658C for 10 min, resolved on 1.5% agarose/formaldehyde gels, and transferred to a Hybond nylon membrane. In addition, nylon membrane containing messenger RNA (mRNA) isolated from various normal human tissues was purchased from Clontech Laboratories (Multiple Tissue Northern (MTN TM ) blot). Caspase-3-specific probe of 824 base pairs (bp) was generated using human mammary epithelial cDNA and caspase-3-specific primers. The PCR product of caspase-3 was oligolabeled with 32 P-a-dCTP by random labeling (Boehringer Mannheim Corp., Indianapolis, IN, USA). Hybridizations were carried out overnight at 428C using random primed labeled caspase-3 probe in Quikhyb (Stratgene, La Jolla, CA, USA) in accordance with the manufacturer's instructions. Furthermore, filters were exposed to autoradiographic film for up to 5 days. To test for the uniform loading of the samples, blots were stripped and reprobed using a cDNA probe for the human 18S rRNA or GAPDH.
The caspase 3 transcript in few selected samples was also determined by using an adaptation of RT -PCR in situ (RT -PCR IS) as described by Bagasara et al. (1993) . The 5'-TTAATAAAGGTATCCATGGAGAACACT-3' primer was labeled with digoxigenin (Sigma Genosys, The Woodland, TX, USA) and PCR was performed for 35 cycles at 948C for 50 s, at 558C for 30 s, and at 728C for 1 min.
Western blot analysis
PBS-washed cells were lysed by sonication in ice-cold buffer A (20 mM Tris-buffered saline (pH 7.4) containing 1 mM EDTA, 14 mM 2-mercaptoethanol, and 1 mM phenylmethylsulfonyl fluoride). Lysed cells were centrifuged at 14 000 r.p.m. for 10 min to remove cell-debris. Protein extracts from breast cancer tissue samples were prepared by either directly grinding the tissue samples using a prechilled mortar and pestle in buffer A or extensively dialyzing the tissue extracts left behind after the total RNA extraction against phosphate-buffered saline containing 0.1% sodium dodecyl sulfate (SDS) (Chomczynski, 1993 ). The dialyzed extracts were then concentrated using Centricon cartridge filter (10 kDa cut-off; Amicon Bioseparations, Bedford, MA, USA), and the protein content in cell and tissue extracts was determined using BioRad dye reagent I (Richmond, CA, USA). Equal amounts of protein (30 -60 mg) were subjected to 12% SDS-polyacrylamide gel electrophoresis (PAGE), and the proteins were transferred onto nitrocellulose membranes. After overnight blocking with 5% nonfat dry milk, the membranes were probed with an anti-caspase-3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1 : 2000, or anti-caspase-8 or anti-caspase-9 antibody (Cell Signaling Technology, Beverly, MA, USA) at a dilution of 1 : 2000. All of the membranes were stripped and reprobed with an anti-b-actin antibody (Sigma Chemical Co, St. Louis, MO, USA) at a dilution of 1 : 2000. The Amersham Pharmacia Biotech ECL system (Piscutaway, NJ, USA) was used to detect the antigen-antibody reaction.
